Boryung Pharmaceutical Co., Ltd.
http://www.boryung.co.kr/eng/index.do
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Boryung Pharmaceutical Co., Ltd.
Korea Q1 Roundup: Pharma Begins To Feel Impact From Doctors’ Walkout
As South Korea's doctors continue their long-running protest against a government plan to raise the medical student quota at universities, the walk-outs may be beginning to take a toll on the pharma industry, with many large firms reporting weak earnings in the last quarter.
Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
TPD A Rising Option For Korean Pharma Seeking New Modalities
Highlighted by SK Biopharmaceuticals’ recent decision to acquire the US-based ProteoVant Sciences, Korean pharma firms are stepping up deals and collaborations in the hot TPD space, which is expected to continue to attract global investors and big pharma interest.
Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice